MedTrace Logo

Targeted Nutrient Supplement in COPD (NUTRECOVER-trial)

NCT03807310 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2025-01-14

No results posted yet for this study

Summary

The overall objective is to investigate the efficacy of targeted nutrient supplementation on daily physical activity level as well as generic health status in patients with COPD. Additionally the investigators aim to investigate the relative effect of targeted nutrient supplementation on the recovery after hospitalization for a COPD exacerbation. The secondary objective is to investigate the effect of targeted nutrient supplementation on mental health, physical performance, blood markers, patient related outcomes and gut health. Additionally, a secondary objective is to compare the gut microbiome composition of patients with COPD compared to healthy controls.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DIETARY_SUPPLEMENT

Targeted nutrient supplementation (Long-drink)

Once daily for at least 12 months

DIETARY_SUPPLEMENT

Placebo supplement

Once daily for at least 12 months

BEHAVIORAL

Counselling

Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing

Sponsors & Collaborators

  • Nutricia Research

    collaborator INDUSTRY

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • Annemie Schols, Prof. dr. · Maastricht UMC+ / NUTRIM, Department of Respiratory Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03807310 on ClinicalTrials.gov